Actinium Pharmaceuticals hosts webinar on ATNM-400 prostate cancer therapy
ATNM•Actinium Pharmaceuticals will host a webinar on its investigational HER3-targeted radiotherapy ATNM-400 on December 1, 2026, at 8 a.m. ET. Management will review initial Phase 1 prostate cancer findings and discuss the RADIANZ imaging study.
1. Webinar topics
Actinium Pharmaceuticals will host a webinar on ATNM-400, with management reviewing initial Phase 1 prostate cancer findings and discussing the RADIANZ imaging study, which is assessing potential across tumor types. Memorial Sloan Kettering Cancer Center's Michael J. Morris will discuss treatment needs in metastatic castration-resistant prostate cancer beyond PSMA-directed therapies.
